Embecta Corp.'s stock plunged 5.99% on Thursday's trading session, following the release of its fiscal Q1 2025 earnings report.
The medical device company reported adjusted earnings of $0.65 per share for the quarter ended December 31, exceeding analysts' expectations of $0.44. However, Embecta lowered its full-year 2025 revenue guidance to $1.08 billion to $1.09 billion, down from the previous range of $1.09 billion to $1.11 billion. This reduced outlook weighed on investor sentiment, leading to the stock's decline.
Despite the revenue guidance cut, Embecta maintained its adjusted earnings per share forecast for fiscal 2025 at $2.70 to $2.90, in line with analysts' estimates of $2.80. The company also reported a dividend of $0.15 for the quarter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.